AZATHIOPRINE INDUCED BONE MARROW SUPPRESSION IN LIVE RELATED RENAL ALLOGRAFT RECIPIENTS.

Area of Science:

• Nephrology
• Immunosuppression
• Hematology

Background:

• Kidney transplantation is a vital treatment for end-stage renal disease.
• Immunosuppressive agents are crucial for preventing allograft rejection.
• Azathioprine is a commonly used immunosuppressant in organ transplantation.

Purpose of the Study:

• To investigate the incidence and clinical presentation of azathioprine-induced bone marrow suppression in live-related renal allograft recipients.
• To characterize the hematological abnormalities and recovery patterns following azathioprine withdrawal.

Main Methods:

• A retrospective analysis of 31 live-related renal allograft recipients over a 6-year follow-up period.
• Monitoring of hematological parameters, including white blood cell count, hemoglobin, and platelet count.
• Clinical assessment for adverse events and graft function.

Main Results:

• Four out of 31 recipients (12.9%) developed azathioprine-induced bone marrow suppression.
• Common presentations included leucopenia (all patients), anemia (2 patients), and pancytopenia (1 patient).
• Bone marrow suppression occurred at a median of 9.6 months post-transplant and resolved within 30 days of drug withdrawal.

Conclusions:

• Azathioprine-induced bone marrow suppression is a significant complication in renal allograft recipients.
• Early recognition and withdrawal of azathioprine are essential for patient recovery.
• Close hematological monitoring is recommended for patients receiving azathioprine post-transplantation.